Related references
Note: Only part of the references are listed.Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression
Sin Ho Kweon et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals
Subash C. Gupta et al.
CANCER AND METASTASIS REVIEWS (2010)
Spontaneous and 5-fluorouracil-induced centrosome amplification lowers the threshold to resveratrol-evoked apoptosis in colon cancer cells
Shao Chin Lee et al.
CANCER LETTERS (2010)
Resveratrol attenuates the anticancer efficacy of paclitaxel in human breast cancer cells in vitro and in vivo
Masayuki Fukui et al.
EUROPEAN JOURNAL OF CANCER (2010)
Resveratrol Induces Cell-Cycle Disruption and Apoptosis in Chemoresistant B16 Melanoma
Gregory Gatouillat et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2010)
Resveratrol confers resistance against taxol via induction of cell cycle arrest in human cancer cell lines
Qi-Qi Mao et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2010)
Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells
Astrid Bernhaus et al.
INVESTIGATIONAL NEW DRUGS (2009)
Resveratrol addiction: To die or not to die
Mehdi Shakibaei et al.
MOLECULAR NUTRITION & FOOD RESEARCH (2009)
Involvement of mitochondria and recruitment of Fas/CD95 signaling in lipid rafts in resveratrol-mediated antimyeloma and antileukemia actions
M. Reis-Sobreiro et al.
ONCOGENE (2009)
Reversal effect of resveratrol on multidrug resistance in KBv200 cell line
Fang Quan et al.
BIOMEDICINE & PHARMACOTHERAPY (2008)
Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis - The roles of caspase-6 and p53 (Publication with Expression of Concern. See vol. 21, pg. 767, 2020)
Jason Yongsheng Chan et al.
CANCER BIOLOGY & THERAPY (2008)
Guggulsterone, a farnesoid X receptor antagonist, inhibits constitutive and inducible STAT3 activation through induction of a protein tyrosine phosphatase SHP-1 (Publication with Expression of Concern. See vol. 78, pg. 5184, 2018)
Kwang Seok Ahn et al.
CANCER RESEARCH (2008)
Resveratrol - A multitargeted agent for age-associated chronic diseases
Kuzhuvelil B. Harikumar et al.
CELL CYCLE (2008)
p53-driven apoptosis limits centrosome amplification and genomic instability downstream of NPM1 phosphorylation
Maria Emanuela Cuomo et al.
NATURE CELL BIOLOGY (2008)
Multiple molecular mechanisms for multidrug resistance transporters
Christopher F. Higgins
NATURE (2007)
Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-κB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells
Anjana Bhardwaj et al.
BLOOD (2007)
c-FLIP inhibits chemotherapy-induced colorectal cancer cell death
DB Longley et al.
ONCOGENE (2006)
Therapeutic potential of resveratrol: the in vivo evidence
Joseph A. Baur et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Effects of dietary chemopreventive phytochemicals on P-glycoprotein function
T Nabekura et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Resveratrol interference with the cell cycle protects human neuroblastoma SH-SY5Y cell from paclitaxel-induced apoptosis
R Rigolio et al.
NEUROCHEMISTRY INTERNATIONAL (2005)
Nuclear factor-κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis
AC Bharti et al.
BLOOD (2004)
Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells
EY Chun et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution
KA Ahmad et al.
CANCER RESEARCH (2004)
Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol
S Fulda et al.
ONCOGENE (2004)
Oncogenic H-ras up-regulates expression of ERCCI to protect cells from platinum-based anticancer agents
CK Youn et al.
CANCER RESEARCH (2004)
Membrane transporters and channels:: Role of the transportome in cancer chemosensitivity and chemoresistance
Y Huang et al.
CANCER RESEARCH (2004)
Natural products as sources of new drugs over the period 1981-2002
DJ Newman et al.
JOURNAL OF NATURAL PRODUCTS (2003)
Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma
Y Aoki et al.
BLOOD (2003)
Validating survivin as a cancer therapeutic target
DC Altieri
NATURE REVIEWS CANCER (2003)
Centrosome aberrations: Cause or consequence of cancer progression?
EA Nigg
NATURE REVIEWS CANCER (2002)
Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells
PJ Real et al.
ONCOGENE (2002)
Nuclear factor-kappa B and cancer: its role in prevention and therapy
AC Bharti et al.
BIOCHEMICAL PHARMACOLOGY (2002)
STATs: Transcriptional control and biological impact
DE Levy et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
IAP proteins: Blocking the road to death's door
GS Salvesen et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
Anti-apoptotic effect of trans-resveratrol on paclitaxel-induced apoptosis in the human neuroblastoma SH-SY5Y cell line
G Nicolini et al.
NEUROSCIENCE LETTERS (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Human ovarian cancer and cisplatin resistance: Possible role of inhibitor of apoptosis proteins
JL Li et al.
ENDOCRINOLOGY (2001)
Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3
XM Chen et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Differential modulation of chemosensitivity to alkylating agents and platinum compounds by DNA repair modulators in human lung cancer cell lines
MM Heim et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2000)
Share Paper
